TPCera

Company Overview

Snapshot

Founded in May 2016 by Yehuda Shoenfeld, Miri Blank, and Tzachy (Isaac) Tal, TPCera operated with 1-10 employees. The company raised a total of $4.39M across three funding rounds from five investors. TPCera ceased operations in October 2022.

Business overview

TPCera is a Health Tech & Life Sciences company focused on developing immunomodulatory compounds to treat autoimmune diseases. The company's core technology involves shifting the immune system from an inflammatory to an anti-inflammatory state, specifically by modulating macrophages from M1 to M2. TPCera's lead compound, TPC1022, demonstrated promising results in preclinical studies for lupus, colitis, and rheumatoid arthritis, serving the pharmaceutical and biotechnology sectors.

Company Intelligence Q&A

What is TPCera's primary focus?

TPCera focuses on developing immunomodulatory compounds designed to shift the immune system from an inflammatory to an anti-inflammatory state, with a specific emphasis on modulating macrophages from M1 to M2 for the treatment of autoimmune diseases.

When was TPCera founded and by whom?

TPCera was founded in May 2016 by Yehuda Shoenfeld, Miri Blank, and Tzachy (Isaac) Tal.

What is TPCera's lead compound?

TPCera's lead compound is TPC1022, which has shown promising results in preclinical studies for autoimmune conditions such as lupus, colitis, and rheumatoid arthritis.

What was the status of TPCera's operations?

TPCera ceased to operate in October 2022.

Which investors participated in TPCera's funding rounds?

TPCera received funding from investors including VLX Ventures and Maruho Israel Innovation Fund.